share_log

Travere Therapeutics Analyst Ratings

Travere Therapeutics Analyst Ratings

Travere Therapeutics 分析师
Benzinga ·  2023/10/25 15:31
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/25/2023 42.1% Piper Sandler $19 → $10 Maintains Neutral
09/29/2023 70.52% Wedbush → $12 Reiterates Outperform → Outperform
09/22/2023 70.52% Barclays $31 → $12 Maintains Overweight
09/22/2023 283.68% B of A Securities $41 → $27 Maintains Buy
09/22/2023 155.78% Guggenheim $25 → $18 Maintains Buy
09/22/2023 98.94% Evercore ISI Group $30 → $14 Maintains Outperform
09/22/2023 155.78% HC Wainwright & Co. $32 → $18 Maintains Buy
09/22/2023 13.68% Wells Fargo $24 → $8 Downgrades Overweight → Equal-Weight
09/21/2023 — William Blair Downgrades Outperform → Market Perform
09/19/2023 326.31% Evercore ISI Group $30 → $30 Maintains Outperform
09/06/2023 326.31% Evercore ISI Group → $30 Reinstates Outperform → Outperform
08/18/2023 169.99% Piper Sandler $22 → $19 Maintains Neutral
08/07/2023 354.73% HC Wainwright & Co. $35 → $32 Reiterates Buy → Buy
07/21/2023 269.47% JP Morgan → $26 Initiates Coverage On → Overweight
07/18/2023 397.36% Canaccord Genuity $37 → $35 Maintains Buy
06/21/2023 226.83% Wedbush → $23 Reiterates Outperform → Outperform
06/07/2023 212.62% Piper Sandler → $22 Assumes → Neutral
06/01/2023 397.36% HC Wainwright & Co. $22 → $35 Reiterates → Buy
05/22/2023 326.31% TD Cowen → $30 Initiates Coverage On → Outperform
05/02/2023 212.62% HC Wainwright & Co. $40 → $22 Maintains Buy
05/02/2023 454.2% B of A Securities $52 → $39 Maintains Buy
05/02/2023 269.47% Evercore ISI Group $36 → $26 Maintains Outperform
05/02/2023 241.04% Wells Fargo $28 → $24 Maintains Overweight
05/02/2023 226.83% Guggenheim $40 → $23 Maintains Buy
04/17/2023 312.1% Wedbush $30 → $29 Maintains Outperform
03/01/2023 425.78% Guggenheim → $37 Initiates Coverage On → Buy
02/28/2023 496.83% Canaccord Genuity $44 → $42 Maintains Buy
02/24/2023 468.41% HC Wainwright & Co. → $40 Reiterates → Buy
02/22/2023 525.25% Canaccord Genuity $40 → $44 Maintains Buy
02/21/2023 553.67% Piper Sandler $42 → $46 Maintains Overweight
02/21/2023 326.31% Wedbush → $30 Upgrades Neutral → Outperform
02/21/2023 340.52% Barclays $37 → $31 Maintains Overweight
02/21/2023 468.41% HC Wainwright & Co. $36 → $40 Reiterates → Buy
02/17/2023 411.57% HC Wainwright & Co. → $36 Reiterates → Buy
01/30/2023 468.41% Canaccord Genuity $33 → $40 Maintains Buy
01/11/2023 496.83% Piper Sandler $38 → $42 Maintains Overweight
12/14/2022 212.62% Stifel → $22 Initiates Coverage On → Hold
12/05/2022 297.89% Wells Fargo → $28 Initiates Coverage On → Overweight
10/20/2022 439.99% SVB Leerink $45 → $38 Maintains Outperform
10/17/2022 411.57% HC Wainwright & Co. $42 → $36 Maintains Buy
10/14/2022 439.99% Piper Sandler $39 → $38 Maintains Overweight
08/08/2022 496.83% HC Wainwright & Co. $46 → $42 Maintains Buy
08/05/2022 539.46% SVB Leerink $42 → $45 Maintains Outperform
07/26/2022 482.62% Piper Sandler $40 → $41 Maintains Overweight
07/14/2022 496.83% Canaccord Genuity → $42 Assumes → Buy
05/17/2022 553.67% HC Wainwright & Co. $45 → $46 Maintains Buy
05/06/2022 468.41% Piper Sandler $42 → $40 Maintains Overweight
03/31/2022 496.83% Piper Sandler → $42 Initiates Coverage On → Overweight
02/28/2022 539.46% HC Wainwright & Co. → $45 Initiates Coverage On → Buy
12/16/2021 468.41% Barclays $36 → $40 Maintains Overweight
12/16/2021 496.83% SVB Leerink $37 → $42 Maintains Outperform
08/17/2021 425.78% SVB Leerink $27 → $37 Maintains Outperform
05/27/2021 539.46% Canaccord Genuity $48 → $45 Maintains Buy
05/26/2021 169.99% Wedbush → $19 Downgrades Outperform → Neutral
05/17/2021 582.09% Canaccord Genuity $51 → $48 Maintains Buy
02/03/2021 624.72% Canaccord Genuity $28 → $51 Maintains Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
2023年10月25日 42.1% 派珀·桑德勒 $19→$10 维护 中性
09/29/2023 70.52% 韦德布什 →$12 重申 跑赢→跑赢大盘
09/22/2023 70.52% 巴克莱 $31→$12 维护 超重
09/22/2023 283.68% B of A证券 $41→$27 维护 买
09/22/2023 155.78% 古根海姆 $25→$18 维护 买
09/22/2023 98.94% Evercore ISI集团 $30→$14 维护 跑赢大盘
09/22/2023 155.78% HC Wainwright公司 $32→$18 维护 买
09/22/2023 13.68% 富国银行 $24→$8 评级下调 超重→等重
2023年09月21日 - 威廉·布莱尔 评级下调 跑赢→市场表现
2023/09/19 326.31% Evercore ISI集团 $30→$30 维护 跑赢大盘
09/06/2023 326.31% Evercore ISI集团 →$30 恢复 跑赢→跑赢大盘
2023年08月18日 169.99% 派珀·桑德勒 $22→$19 维护 中性
08/07/2023 354.73% HC Wainwright公司 $35→$32 重申 购买→购买
07/21/2023 269.47% 摩根大通 →$26 开始承保 →超重
07/18/2023 397.36% 卡纳科特·格纳奇 $37→$35 维护 买
2023年6月21日 226.83% 韦德布什 →$23 重申 跑赢→跑赢大盘
06/07/2023 212.62% 派珀·桑德勒 →$22 假设 →中性
06/01/2023 397.36% HC Wainwright公司 $22→$35 重申 →购买
2023年05月22日 326.31% TD Cowen →$30 开始承保 →跑赢大盘
05/02/2023 212.62% HC Wainwright公司 $40→$22 维护 买
05/02/2023 454.2% B of A证券 $52→$39 维护 买
05/02/2023 269.47% Evercore ISI集团 $36→$26 维护 跑赢大盘
05/02/2023 241.04% 富国银行 $28→$24 维护 超重
05/02/2023 226.83% 古根海姆 $40→$23 维护 买
04/17/2023 312.1% 韦德布什 $30→$29 维护 跑赢大盘
03/01/2023 425.78% 古根海姆 →$37 开始承保 →购买
02/28/2023 496.83% 卡纳科特·格纳奇 $44→$42 维护 买
02/24/2023 468.41% HC Wainwright公司 →$40 重申 →购买
02/22/2023 525.25% 卡纳科特·格纳奇 $40→$44 维护 买
02/21/2023 553.67% 派珀·桑德勒 $42→$46 维护 超重
02/21/2023 326.31% 韦德布什 →$30 升级 中性→表现优异
02/21/2023 340.52% 巴克莱 $37→$31 维护 超重
02/21/2023 468.41% HC Wainwright公司 $36→$40 重申 →购买
02/17/2023 411.57% HC Wainwright公司 →$36 重申 →购买
2023年1月30日 468.41% 卡纳科特·格纳奇 $33→$40 维护 买
2023年1月11日 496.83% 派珀·桑德勒 $38→$42 维护 超重
2022年12月14日 212.62% Stifel →$22 开始承保 →保留
12/05/2022 297.89% 富国银行 →$28 开始承保 →超重
10/20/2022 439.99% SVB Leerink $45→$38 维护 跑赢大盘
10/17/2022 411.57% HC Wainwright公司 $42→$36 维护 买
10/14/2022 439.99% 派珀·桑德勒 $39→$38 维护 超重
2022/08/08 496.83% HC Wainwright公司 $46→$42 维护 买
08/05/2022 539.46% SVB Leerink $42→$45 维护 跑赢大盘
07/26/2022 482.62% 派珀·桑德勒 $40→$41 维护 超重
07/14/2022 496.83% 卡纳科特·格纳奇 →$42 假设 →购买
2022/05/17 553.67% HC Wainwright公司 $45→$46 维护 买
05/06/2022 468.41% 派珀·桑德勒 $42→$40 维护 超重
03/31/2022 496.83% 派珀·桑德勒 →$42 开始承保 →超重
02/28/2022 539.46% HC Wainwright公司 →$45 开始承保 →购买
12/16/2021 468.41% 巴克莱 $36→$40 维护 超重
12/16/2021 496.83% SVB Leerink $37→$42 维护 跑赢大盘
2021/08/17 425.78% SVB Leerink $27→$37 维护 跑赢大盘
2021/05/27 539.46% 卡纳科特·格纳奇 $48→$45 维护 买
2021/05/26 169.99% 韦德布什 →$19 评级下调 跑赢→中性
2021/05/17 582.09% 卡纳科特·格纳奇 $51→$48 维护 买
02/03/2021 624.72% 卡纳科特·格纳奇 $28→$51 维护 买

What is the target price for Travere Therapeutics (TVTX)?

Travere Treeutics(TVTX)的目标价格是多少？

The latest price target for Travere Therapeutics (NASDAQ: TVTX) was reported by Piper Sandler on October 25, 2023. The analyst firm set a price target for $10.00 expecting TVTX to rise to within 12 months (a possible 42.10% upside). 38 analyst firms have reported ratings in the last year.

派珀·桑德勒于2023年10月25日报道了Travere治疗公司(纳斯达克代码：TVTX)的最新目标价。这家分析公司将目标价定为10.00美元，预计TVTX将在12个月内上涨(可能上涨42.10%)。去年有38家分析公司公布了评级。

What is the most recent analyst rating for Travere Therapeutics (TVTX)?

Travere Treeutics(TVTX)的最新分析师评级是什么？

The latest analyst rating for Travere Therapeutics (NASDAQ: TVTX) was provided by Piper Sandler, and Travere Therapeutics maintained their neutral rating.

派珀·桑德勒对特拉华治疗公司(纳斯达克股票代码：TVTX)的最新分析师评级是由派珀·桑德勒提供的，特拉维尔治疗公司维持其中性评级。

When is the next analyst rating going to be posted or updated for Travere Therapeutics (TVTX)?

Travere Treeutics(TVTX)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Travere Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Travere Therapeutics was filed on October 25, 2023 so you should expect the next rating to be made available sometime around October 25, 2024.

分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Travere Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Travere治疗公司的上一次评级是在2023年10月25日提交的，所以你应该预计下一次评级将在2024年10月25日左右的某个时候提供。

Is the Analyst Rating Travere Therapeutics (TVTX) correct?

分析师对Travere Treeutics(TVTX)的评级正确吗？

While ratings are subjective and will change, the latest Travere Therapeutics (TVTX) rating was a maintained with a price target of $19.00 to $10.00. The current price Travere Therapeutics (TVTX) is trading at is $7.04, which is out of the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的Travere Treateutics(TVTX)评级保持不变，目标价在19.00美元至10.00美元之间。Travere Treateutics(TVTX)目前的交易价格为7.04美元，超出了分析师的预测范围。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发